Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $119.66 is 36.77% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 121.91||$ 183.60|
|Low:||$ 118.52||$ 87.49|
Company Description (as filed with the SEC)
We are a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. With our lentiviral-based gene therapy and gene editing capabilities, we have built an integrated product platform with broad therapeutic potential in a variety of indications. We believe that gene therapy for severe genetic diseases has the potential to change the way patients living with these diseases are treated by addressing the underlying genetic defect that is the cause of their disease, rather than offering treatments that only address their symptoms. Our clinical programs in severe genetic diseases include our LentiGlobin® product candidate as a treatment for transfusion-dependent ?-thalassemia, or TDT, and sickle cell disease, or SCD, and our Lenti-D(TM) product candidate as a treatment for cerebral adrenoleukodystrophy, or CALD. ... More ...
Nasdaq Official Price
Jun. 26, 2019
Jun. 26, 2019